NeurologyLive® Friday 5 — July 21, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Alzheimer Disease Pipeline Update: Inside Look at Promising Agents

With the recent approval of lecanemab (Leqembi; Eisai), NeurologyLive took a closer look at the Alzheimer pipeline, and the potential agents clinicians should keep an eye on in the coming years.

2: Peer Exchange: Access to and Challenges to Biosimilar use in Clinical Practice

In episode 8 of the "How Similar are Biosimilars? A look into the Future with Biosimilars in Multiple Sclerosis" Peer Exchange series, John Kramer, PA-C, Patricia Melville, NP-C, and Amy Perrin Ross, APN identify challenges in accessing biosimilars in clinical practice.

3: NeuroVoices: Dustin Hammers, PhD, on Comparative Performance of Cognitive Screening Techniques

In the latest edition of our in-depth Q&A series, the associate professor of neurology at the Indiana University School of Medicine provided commentary on a study comparing traditional cognitive screening methods and the Linus Health Digital Clock and Recall test.

4: Future Leaders in Neurology: Pregnancy in MS Patients

Elisabeth Lucassen, MD, provides an overview of the impact of pregnancy in multiple sclerosis (MS) patients, the management of MS and pregnancy, and the use of disease-modifying therapies in pregnancy and breastfeeding.

5: Differences in Available Cognitive Screening Tools: Dustin Hammers, PhD

The associate professor of neurology at the Indiana University School of Medicine provided insight on the distinguishable characteristics of certain cognitive screening tools and the advantages to each. [WATCH TIME: 3 minutes]